Summer Special! Get NewsNow Essentials at just £1.99 a month (50% OFF!). Faster, slicker, customisable & ad free!Summer Special! Get NewsNow Essentials at just £1.99 a month (50% OFF!). Subscribe and saveSummer Special! Upgrade here at £1.99/m (50% OFF!)

Home
Hot Topics
Australia
World
Sport
Business
Entertainment
Science
Technology
Lifestyle

Biogen
Biotech
Topics

Advertisement

Advertisement

Biogen

Share

Top Latest Popular

Friday

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Biogen (Press Release) 00:37 Fri, 04 Sep

Thursday

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China Biogen (Press Release) 05:06 Thu, 03 Sep

Tuesday

Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersen RTT News 14:04 Tue, 01 Sep

Advertisement

Advertisement

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Biogen (Press Release) 12:38 Tue, 01 Sep

Biogen: Canada's Drug Agency Supports Public Reimbursement Of Leqembi RTT News 06:46 Tue, 01 Sep

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease Biogen (Press Release) 00:36 Tue, 01 Sep

In the last month

Why Veeva Systems (VEEV) Is Up 11.6% After Strong Q2, Higher Guidance, and New AI CRM Wins Simply Wall St 09:22 Sun, 30 Aug

Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Biogen (Press Release) 21:15 Thu, 27 Aug

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease JCN Newswire 20:00 Thu, 27 Aug

Leqembi Iqlik launches in US for early Alzheimer’s PharmaTimes 10:51 Wed, 26 Aug

Biogen Expands Digital Strategy With Veeva Vault CRM RTT News 03:52 Wed, 26 Aug

Biogen entscheidet sich für Veeva Vault CRM PR Newswire (Press Release) 00:37 Wed, 26 Aug

Biogen to Participate in the Wells Fargo 21st Annual Healthcare Conference Biogen (Press Release) 21:09 Tue, 25 Aug

Skyclarys approved: HSE to fund Friedreich’s Ataxia drug for Irish patients JOE.ie 15:41 Tue, 25 Aug

HSE approves reimbursement of treatment for patients with rare disorder Irish Mirror 15:01 Tue, 25 Aug

Veeva Vault CRM seleccionado por Biogen PR Newswire (Press Release) 14:41 Tue, 25 Aug

Advertisement

Friedreich’s ataxia: What is it, and how can Skyclarys help patients? Irish Examiner 13:47 Tue, 25 Aug

HSE approves Skyclarys funding for Friedreich’s ataxia patients after campaign Irish Examiner 12:26 Tue, 25 Aug

Biogen a choisi Veeva Vault CRM PR Newswire (Press Release) 12:18 Tue, 25 Aug

Veeva Vault CRM Selected by Biogen PR Newswire (Press Release) 12:03 Tue, 25 Aug

Decision due on Skyclarys funding as Biogen reportedly makes lower price offer Irish Examiner 11:25 Tue, 25 Aug

Uncertainty over Skyclarys decision as HSE team to meet RTE 06:08 Tue, 25 Aug

Talks on Skyclarys have reached a critical point – David Cullinane TD Sinn Féin (Press Release) 18:20 Mon, 24 Aug

Biogen And Eisai Launch Leqembi Iqlik Autoinjector For Early Alzheimer's In U.S. RTT News 14:02 Mon, 24 Aug

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease Biogen (Press Release) 13:12 Mon, 24 Aug

Leqembi Iqlik®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease PR Newswire (Press Release) 13:04 Mon, 24 Aug

Will FDA Approve Biogen’s Promising New Treatment for Alzheimer’s? The Independent Institute (Weblog) 14:13 Sun, 23 Aug

HSE to decide on €280,000-a-year Skyclarys drug for Friedreich’s ataxia Irish Examiner 15:13 Sat, 22 Aug

'A problematic child': Ireland's rare drugs record casts doubt over Skyclarys decision Irish Examiner 06:43 Sat, 22 Aug

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? Zacks 16:24 Thu, 20 Aug

Is Wall Street Bullish or Bearish on Biogen Stock? Barchart 13:36 Thu, 20 Aug

Skyclarys maker disputes figures cited in HSE decision not to fund the drug Irish Examiner 19:00 Tue, 18 Aug

Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit? Simply Wall St 20:43 Fri, 07 Aug

Biogen, Investors Reach Settlement Outline Over Alzheimer’s Drug Bloomberg Law 17:31 Fri, 07 Aug

Advertisement

Advertisement

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Biotech Biotech
Back to Business Biotech
- GM Food GM Food
- AbbVie AbbVie
- Amgen Amgen
- Biogen Biogen
- BioNTech BioNTech
- Celltrion Celltrion
- Genentech Genentech
- Gilead Sciences
- Illumina Illumina
- Moderna Moderna